Nguyen Geoffrey C, Kaplan Gilaad G, Harris Mary L, Brant Steven R
Mount Sinai Hospital IBD Centre, University of Toronto School of Medicine, Toronto, Ontario, Canada.
Am J Gastroenterol. 2008 Jun;103(6):1443-50. doi: 10.1111/j.1572-0241.2007.01780.x. Epub 2008 May 29.
We sought to determine nationwide, population-based trends in rates of Clostridium difficile (C. difficile) infection among hospitalized inflammatory bowel disease (IBD) patients in the United States, and to determine its mortality and economic impact.
We analyzed discharge records from the Nationwide Inpatient Sample, and used the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to identify Crohn's disease (CD) and ulcerative colitis (UC) cases, and cases of C. difficile infection between 1998 and 2004. Temporal patterns of C. difficile incidence in IBD patients were compared to non-IBD gastroenterology patients and all-hospitalized patients. The impact of C. difficile on in-hospital mortality and resource utilization was quantified using multiple regression analysis.
The prevalence of C. difficile among UC patients (37.3 per 1,000, 95% confidence interval [CI] 34.0-40.7 per 1,000) was higher than that among CD patients (10.9 per 1,000, 95% CI 9.9-12.0 per 1,000), non-IBD gastrointestinal (GI) patients (4.8 per 1,000, 95% CI 4.6-5.0 per 1,000), and general medical patients (4.5 per 1,000, 95% CI 4.2-4.7 per 1,000). C. difficile incidence nearly doubled among UC patients (26.6 per 1,000 to 51.2 per 1,000) over 7 yr. After adjustment for confounders, C. difficile infection was associated with greater mortality among patients with UC (odds ratio [OR] 3.79, 95% CI 2.84-5.06), but not CD (OR 1.66, 95% CI 0.75-3.66). C. difficile was also associated with 65% and 46% longer lengths of stay, which correlated with 63% and 46% higher average hospital charges, for CD and UC patients, respectively.
C. difficile infection is a growing public health issue among hospitalized IBD patients, especially those with UC, and is associated with higher mortality and resource utilization, prompting the need for better preventative measures and early detection.
我们试图确定美国住院炎性肠病(IBD)患者中艰难梭菌(C. difficile)感染率的全国性、基于人群的趋势,并确定其死亡率和经济影响。
我们分析了全国住院患者样本中的出院记录,并使用国际疾病分类第九版临床修订本(ICD-9-CM)编码来识别克罗恩病(CD)和溃疡性结肠炎(UC)病例以及1998年至2004年间的艰难梭菌感染病例。将IBD患者中艰难梭菌感染的时间模式与非IBD胃肠病患者及所有住院患者进行比较。使用多元回归分析量化艰难梭菌对住院死亡率和资源利用的影响。
UC患者中艰难梭菌的患病率(每1000人中有37.3例,95%置信区间[CI]为每1000人34.0 - 40.7例)高于CD患者(每1000人中有10.9例,95%CI为每1000人9.9 - 12.0例)、非IBD胃肠道(GI)患者(每1000人中有4.8例,95%CI为每1000人4.6 - 5.0例)以及普通内科患者(每1000人中有4.5例,95%CI为每1000人4.2 - 4.7例)。7年间,UC患者中艰难梭菌感染率几乎翻了一番(从每1000人26.6例增至每1000人51.2例)。在对混杂因素进行调整后,艰难梭菌感染与UC患者的较高死亡率相关(比值比[OR]为3.79,95%CI为2.84 - 5.06),但与CD患者无关(OR为1.66,95%CI为0.75 - 3.66)。艰难梭菌感染还分别使CD和UC患者的住院时间延长65%和46%,这与平均住院费用分别高出63%和46%相关。
艰难梭菌感染是住院IBD患者中日益严重的公共卫生问题,尤其是UC患者,且与较高的死亡率和资源利用相关,这促使需要更好的预防措施和早期检测。